13 Dec, 2011 Alnylam Scientists Present Data on RNAi Therapeutics at 53rd ASH Annual Meeting
In December 2011, our scientists presented multiple posters and presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, CA. We shared data from two programs within our “Alnylam 5×15” product pipeline, including pre-clinical data from ALN-APC, an RNAi therapeutic targeting protein C for the treatment of hemophilia,…
and ALN-HPN, an RNAi therapeutic targeting the hepcidin pathway for the treatment of refractory anemia. In addition, we presented pre-clinical research from two candidate programs in beta-thalassemia and erythropoiesis.
Research presented at this meeting highlights the significant progress we are making in translating RNAi therapeutics toward an innovative class of medicines. It is worth noting that all four programs are focused on genetically defined targets expressed in the liver, where we have recently proven safe and effective delivery in man, with target and/or disease biomarkers measureable in early clinical studies.